Related Experiment Video

Updated: Mar 24, 2026

Demonstrating a Linear Relationship Between Vascular Endothelial Growth Factor and Luteinizing Hormone in Kidney Cortex Extracts
05:56

Demonstrating a Linear Relationship Between Vascular Endothelial Growth Factor and Luteinizing Hormone in Kidney Cortex Extracts

Published on: January 22, 2020

5.3K

Anti-VEGF-Induced Hypertension: a Review of Pathophysiology and Treatment Options

Bryan J Brinda1, Federico Viganego2, Teresa Vo3

  • 1Department of Pharmacy, H. Lee Moffitt Cancer Center & Research Institute, 12902 USF Magnolia Drive, Tampa, FL, 33612, USA. bryan.brinda@moffitt.org.

Current Treatment Options in Cardiovascular Medicine
|March 3, 2016
PubMed
Abstract

Insights

Vascular Endothelial Growth Factor (VEGF) inhibitors improve cancer treatment but can cause hypertension. Managing this side effect is crucial for patients undergoing anti-angiogenic therapy.

Area of Science:

  • Oncology
  • Cardiovascular Medicine
  • Pharmacology

Background:

  • Cancer therapies targeting intracellular signaling pathways have improved outcomes.
  • Cardiovascular toxicity, including hypertension, is a significant complication of these treatments.
  • Angiogenesis, crucial in cancer, is targeted by Vascular Endothelial Growth Factor (VEGF) inhibitors.

Purpose of the Study:

  • To comprehensively review hypertension induced by VEGF inhibitors.
  • To discuss the pathophysiology, common agents, and treatment strategies for VEGF-induced hypertension.

Main Methods:

  • Literature review of studies on VEGF inhibitors and hypertension.
  • Analysis of the mechanisms underlying VEGF inhibitor-induced hypertension.
  • Synthesis of current treatment guidelines and options.

Main Results:

  • VEGF inhibitors can lead to hypertension, a common and potentially serious adverse event.
  • Hypertension may necessitate premature treatment cessation if not adequately controlled.
  • Understanding the pathophysiology is key to managing this toxicity.

Conclusions:

  • VEGF inhibitors offer therapeutic benefits in oncology but pose cardiovascular risks.
  • Effective blood pressure management is essential for patients receiving VEGF inhibitors.
  • Further research into managing VEGF-induced hypertension is warranted.
Keywords:
AngiogenesisCardio-oncologyCardiotoxicityHypertensionTyrosine kinase inhibitorsVEGF inhibitors

More Related Videos

Author Spotlight: Overcoming Anti-VEGF Resistance Through Advanced Vascular Morphology Assessment in Choroidal Neovascularization05:14

Author Spotlight: Overcoming Anti-VEGF Resistance Through Advanced Vascular Morphology Assessment in Choroidal Neovascularization

Published on: August 11, 2023

1.7K
A Simple Bioassay for the Evaluation of Vascular Endothelial Growth Factors09:04

A Simple Bioassay for the Evaluation of Vascular Endothelial Growth Factors

Published on: March 15, 2016

10.3K

Related Concept Videos

Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
3.9K
Hypertension II: Pathophysiology01:29

Hypertension II: Pathophysiology

Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
1.4K
Hypertension and Regulation of Blood Pressure01:18

Hypertension and Regulation of Blood Pressure

Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
4.7K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
544
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
2.8K
Hypertension I: Introduction01:28

Hypertension I: Introduction

Hypertension is a widespread, long-term medical condition where blood pressure in the arteries remains elevated. It is characterized by systolic blood pressure readings of 130 mm Hg or above or diastolic blood pressure (DBP) readings of 80 mm Hg or higher. Unmanaged hypertension poses significant health risks, making the distinction between primary (or essential) hypertension and secondary hypertension crucial, as their management and implications vary.Primary HypertensionPrimary hypertension,...
1.2K